Cardiovascular disease (CVD) is the leading cause of death worldwide, and scalable, non-invasive biomarkers for CVD are a growing area of research interest.1 Ideally, a CVD biomarker would accurately identify high-risk individuals, convey prognostic value, and allow early intervention in the disease course. Increased urinary albumin excretion is a known CVD risk factor among patients with diabetes, hypertension, chronic kidney disease (CKD), coronary artery disease, and heart failure,2 and may even convey risk among those with few CVD risk factors.3–5 Albuminuria is also a strong determinant of CKD progression in patients with and without metabolic diseases.6 Therefore, urinary albumin-to-creatinine ratio (UACR) is an attractive, unifying biomarker of cardiovascular, kidney, and metabolic conditions that may be useful for identifying and monitoring disease trajectory. The dose-response relationship between UACR and cardiovascular outcomes make this biomarker particularly relevant to Cardiology clinical practice.7–9This narrative, state-of-the-art review discusses the role of albuminuria in cardiovascular, kidney, and metabolic conditions and identifies potential pathways linking albuminuria to adverse cardiovascular outcomes. This review highlights the importance of testing for albuminuria in cardiovascular practice and provides suggestions for evidence-based treatment initiation in patients with cardiovascular, kidney, and metabolic disorders.In clinical practice, spot urine albumin is quantified using a fluorescent immunoassay or liquid chromatography and spot urine creatinine is measured using a standardized enzymatic method or the Jaffe reaction.10 While 24-hour urine collection is preferred, spot urinary albumin-to-creatinine ratio (UACR) is suitable for most clinical scenarios, so long as the assumption that an individual excretes ~1000 mg/day of creatinine holds.11 These quantitative methods are strongly preferred to urine dipstick analysis, which has low sensitivity and detects only advanced albuminuria (typically ≥300 mg/g).12 The value of dipstick proteinuria analysis is in the widespread availability and affordability that may increase screening in resource-constrained settings. However, where possible, quantitative methods are preferred (Table 1).Under normal physiologic conditions, up to several grams of albumin may be filtered and reabsorbed by the early proximal tubule (either intact or following catabolism), though the precise glomerular sieving coefficient is debated (Figure 1).13–15 Protein that is excreted into the urine can be benign or pathologic.11 Transient causes of proteinuria include fever, orthostatic proteinuria, urinary tract infection, pregnancy, or vigorous exercise. Transient proteinuria can also be seen in patients with severe hypertension, poor glycemic control, and severe hyperlipidemia.11 Persistent proteinuria is pathologic and may be tubular (albumin and non-albumin protein) or glomerular (albumin-predominant) in etiology.11 16,17,18Glomerular proteinuria results from foot process effacement, glomerular basement membrane injury, or increased glomerular hydrostatic pressure that disrupts selective glomerular ultrafiltration.16 Albuminuria may be detectable in kidney disease before a decline in glomerular filtration rate (GFR).17
Current clinical practice guidelines classify a UACR measurement of <30 mg/g (<3.4 mg/mmol) as ‘normal to minimally increased’, 30-300 mg/g (3.4-34 mg/mmol) as ‘moderately increased,’ and ≥300 mg/g (34 mg/mmol) as ‘severely increased.’18 Albuminuria above 3.0-3.5 g/day is considered ‘nephrotic range’. However, it is well recognized that a continuous relationship exists between increasing albuminuria and adverse clinical outcomes that begins far below the traditional ‘microalbuminuria’ threshold (<30 mg/g).4–6,19,20 Prior authors have articulated issues with the current albuminuria classification system, principally the over-emphasis on thresholds.21,22 The false dichotomization between ‘normal’ and ‘abnormal’ UACR at 30 mg/g obscures risk and may predispose clinicians to overlook opportunities for cardiorenal risk reduction. A new framework which incorporates the continuous relationship may improve clinical management of albuminuria, though multiple additional knowledge gaps remain (Table 2).
One of the pitfalls of measuring albuminuria is the day-to-day variability in an individual’s urinary albumin excretion.23,24 Therefore, repeat quantitative measurements are required for confirmation.23 This is especially true in diabetes-associated CKD, where a repeated measurement of UACR can vary from 25% to 375% of the initial value,24 though this variation may also be seen in other forms of CKD.23
There are multiple mechanisms by which albuminuria can develop. These phenotypes of albuminuria and proposed mechanisms are summarized in Figure 2. In many patients, however, there may be overlapping or concomitant mechanisms by which albuminuria develops.
In patients with CKD, podocyte foot process effacement leads to insufficient counterpressure and relaxation of the glomerular basement membrane (GBM) fiber matrix.25,26 This causes increased glomerular capillary wall permeability and results in albuminuria. As glomerular disease progresses, the subpodocyte space may widen to cover a greater proportion of the filtration membrane and modulate filtration barrier permeability.27 Expansion of the subpodocyte space and an increase in hydraulic resistance can lead to further podocyte detachment and worsening albuminuria.27 Alternatively, or concurrently, albuminuria can arise from impaired albumin reabsorption in the proximal tubule.13,28
In patients with hypertension, increased intraglomerular pressure causes glomerular hyperfiltration and hyperpermeability, while ongoing intraglomerular capillary endothelial damage can result in capillary albumin leak.29,30 In one study, patients with albuminuria demonstrated normal tubular albumin reabsorption, indicating that hypertension increases glomerular albuminuria.31
In patients with heart failure, elevated central venous pressure can cause low renal perfusion pressure,32,33 chronic tubulointerstitial damage,34–36 or renal congestion,35 any of which may precipitate albuminuria. Volume overload also increases release of natriuretic peptides, which may cause damage to the endothelial glycocalyx,37 though this is debated,38 and result in albuminuria.36 Aldosterone escape in heart failure leads to sodium and water retention, as well as kidney fibrosis.39 More broadly, increased aldosterone levels are associated with increased albuminuria.40–43 Finally, high intraglomerular pressure increases transcapillary flux of the ultrafiltrate and results in albuminuria.44
In patients with atherosclerotic cardiovascular disease, albuminuria can develop secondary to endothelial inflammation and endothelial dysfunction.45,46 Endothelial disturbances are common in sustained atherogenic states and dyslipidemia. Albuminuria is associated with loss of the endothelial glycocalyx,47 dynamic vascular elasticity,48–50 perfusion,51,52 and serologic markers of vascular health (such as nitric oxide and von Willebrand factor).53,54 In one study, the authors argue that increased lipid infiltration of vascular structures increases glomerular transcapillary albumin leak.45 Other common disturbances in atherosclerotic disease include reduced nitric oxide bioavailability, which promotes arterial stiffness and impaired vasodilation.55
In patients with diabetes, many of whom also have metabolic syndrome, albuminuria may develop secondary to either alterations to glomerular charge selectivity or impaired proximal tubular albumin reabsorption.56 Change in GBM size selectivity does not appear to be a contributing factor.56 The Steno hypothesis argues that albuminuria is a consequence of global intima damage due to alterations in the extracellular matrix.57,58 Serum albumin glycosylation is likely one mechanism by which albumin is able bypass GBM charge selectivity in diabetes.59 Alterations to GBM proteoglycans also disrupt charge selectivity.59,60 Insulin resistance can lead to endothelial dysfunction, while impaired vasodilation in the setting of reduced nitric oxide further impairs renal autoregulation.55,61 Global alterations to the endothelium, as measured by von Willebrand factor, may precede albuminuria in diabetes.62
Albuminuria is strongly associated with CVD mortality7,20,63,64 and all-cause mortality in diverse populations.7–9 Similarly, albuminuria is longitudinally associated with major cardiovascular complications such as nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, peripheral artery revascularization.7,64–66 Albuminuria has also been identified as an independent risk factor for stroke and other cerebrovascular diseases.67–69
Multiple authors have described associations between albuminuria and CVD risk factors. For example, albuminuria has been associated with left-ventricular hypertrophy,49,70,71 vascular stiffness and remodeling,49,50,52,72,73 progression of coronary artery calcification.74 Each of these conditions confers a high risk of CVD events and demonstrates the likely systemic vascular pathology associated with albuminuria.
Perhaps the most well-described relationships between albuminuria and CVD are in the context of heart failure.44 Approximately 32% of U.S. adults with heart failure have albuminuria ≥30 mg/g.75 Albuminuria is not only associated with greater risk of incident heart failure76 and diastolic dysfunction,70 but also confers risk of worsening CVD in patients with pre-existing heart failure regardless of ejection fraction.77 Development of albuminuria is strongly associated with adverse outcomes such as increased hospitalizations for heart failure,64,78 systemic vascular congestion,34 and progressive systolic dysfunction.77 While albuminuria is known to improve risk stratification in heart failure, current heart failure society guidelines do not comment on the need for albuminuria screening in this population.79
In general, studies of albuminuria and CVD are performed in populations already at high cardiovascular risk and therefore offer limited insight into the mechanism behind the association of albuminuria and CVD mortality. Associations between albuminuria and incident hypertension80 and incident atrial fibrillation81,82 provide only slightly more evidence that interim development of additional CVD risk factors may contribute to the association with mortality, however, further work is needed.46 One hypothesis is that the presence of albuminuria represents a systemic micro-inflammatory state characterized by diffuse endothelial dysfunction. This is supported by an association between albuminuria and elevated cardiac troponin T in adults without known CVD.83
Notably, albuminuria does not need to be high-grade to convey cardiovascular risk. One study found a linear association between low levels of albuminuria (UACR < 30 mg/g) and CVD mortality among adults without major cardiovascular risk factors.20 In this and several other recent papers, cardiovascular risk appears to increase at UACR approximately 7-10 mg/g.20,84,85 Low-grade albuminuria has been associated with adverse cardiovascular risk factors, including incident hypertension,63 heart failure,76 and coronary artery disease,19 as well as major adverse cardiovascular events4,5,7,65 and mortality.4,19,20 Data from the CKD Prognosis Consortium shows that low levels of albuminuria are associated with major adverse cardiovascular events in diverse populations with CKD.7
While not all patients with CKD have albuminuria, increased urinary albumin excretion above 30 mg/g is one diagnostic criterion for CKD and albuminuria screening is standard component of the clinical CKD workup.18 However, lower levels of albuminuria are also a risk factor for incident CKD.86,87 In patients with CKD, albuminuria below 30 mg/g is linearly associated with increased risk of CKD progression and incident ESKD.6 Risk for CKD progression appears to increase at UACR approximately 7-10 mg/g. Greater albuminuria and changes in albuminuria are independently associated with CKD progression and end-stage kidney disease (ESKD) in patients with and without diabetes.7,88–90
Diabetes is the most common cause of CKD worldwide. Albuminuria is a common consequence of diabetes due to the sustained hyperglycemia, inflammation, and glomerular hyperfiltration that accompanies longstanding diabetes.91 Early studies of diabetes, kidney function, and UACR were limited by small sample sizes and lack of biopsy confirmation to determine whether changes consistent with DKD were present histologically.92 The classic trajectory of diabetic kidney disease (DKD) includes progressive albuminuria and eGFR decline. Greater albuminuria in DKD has been previously associated with increased risk of progressing to ESKD91 and a higher risk of adverse cardiovascular outcomes.93,94 Rising UACR may precede a decline in eGFR for patients with progressive DKD, making it a useful prognostic marker for patients with the ‘classical’ DKD phenotype.91 A subset of patients with diabetes exhibit non- or minimally albuminuric disease phenotypes and nonetheless experience progressive eGFR decline.91,95 An even smaller proportion of patients experience albuminuria regression and stabilization of kidney function. However, in one study, the risk for adverse CVD outcomes remained elevated in these patients.96 Patterns of albuminuria prevalence and trajectories vary between type 1 and type 2 diabetes.91 A greater proportion of patients with type 2 diabetes progress to diabetic nephropathy compared to those with type 1 diabetes.97 While patients with type 2 diabetes can frequently experience regression of albuminuria, patients with type 1 diabetes who develop CKD often exhibit progressive albuminuria over time.91.
A major limitation of the existing literature on the relationship between metabolic syndrome, MASLD, dysglycemia, and albuminuria is the reliance on cross-sectional studies.98,99 Here we briefly outline the work examining albuminuria in the context of these metabolic-associated conditions, acknowledging the limitations.
Multiple measures of adiposity have been associated with albuminuria.100 Central obesity, specifically, may be a crucial risk factor for incident albuminuria independent of diabetes status.100–103 Obesity is an increasingly common etiology of secondary FSGS, which is characterized by significant proteinuria.104 Obesity-associated FSGS typically involves an indolent course followed by progression to ESKD. It is hypothesized that increased oxidative stress, generalized inflammation, chronic glomerular hypoxia, and insulin resistance in obesity lead to the histologic changes in obesity-associated FSGS.104 In patients with obesity, elevated intra-renal resistance on doppler ultrasound is associated with albuminuria, suggesting a possible mechanistic link between adiposity and the development of CKD and CVD events.105–107 However, this cross-sectional evidence precludes any conclusions about causal pathways.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with albuminuria in epidemiologic studies and is a prominent CVD risk factor. Several studies have found an association between MASLD and albuminuria,108,109 with one study noting that the association was independent of insulin resistance or obesity.110 Albuminuria below 30 mg/g may also be a risk factor for developing MASLD, as shown in one prospective, population-based study of Chinese adults.111 In this study, risk appeared to increase at UACR around 2.5 mg/g. While the pathophysiology of how albuminuria may lead to steatotic liver disease – and the reverse -- are not clear, the epidemiologic association may be driven by a generalized state of endothelial inflammation or the incident development of obesity.
Insulin resistance – a key risk factor for metabolic syndrome, diabetes, MASLD, and CVD – is closely associated with albuminuria in patients without diabetes,98,112 as well as those with prediabetes.99 In patients without diabetes, insulin resistance and elevated glomerular hydrostatic pressure were cross-sectionally associated with albuminuria.98 Longitudinally, elevated baseline HOMA-IR in adults without diabetes was associated with subsequent development of albuminuria.112 Inflammatory or oxidative pathways may mediate the relationship between dysglycemia and albuminuria, though this hypothesis has yet to be explored.
It is well described that CKD increases the risk of incident CVD events and CVD events increase the risk of CKD progression.113,114 Cardio-kidney protective medications with antiproteinuric effects reduce incident CVD events and CVD mortality in high-risk populations, likely due to multifactorial pathways and mechanisms not directly related to albuminuria reduction.115,116 These therapies include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor-blockers (ARB), sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP1-RA), and mineralocorticoid receptor antagonists (MRA). Importantly, the more recent cardiovascular and kidney trials on SGLT2i, GLP1-RA, and non-steroidal MRA demonstrate benefit among patients already treated with maximal ACEi/ARB. The additive benefit of these therapies has the potential to improve global cardiovascular outcomes, with the greatest evidence to date among patients with type 2 diabetes.117 Table 3 highlights recent cardiovascular trials which enrolled based on albuminuria, similar to other risk factor-based enrollment criteria (e.g., diabetes, prior CVD).
The mechanisms by which cardio-kidney protective and antiproteinuric therapies provide CVD benefit are only partially understood. ACEi/ARB and angiotensin-receptor/neprilysin inhibitors (ARNI) improve cardiac remodeling following myocardial infarction.118,119 Similarly, steroidal MRA, which have antiproteinuric effects, have been used for decades to improve CVD outcomes in patients with heart failure with reduced ejection fraction and new data show benefit of non-steroidal MRA in these patients with preserved ejection fraction.120 The CVD protective effects of SGLT2i may be driven primarily by a reduction in hospitalization for heart failure,121 while the benefits of GLP1-RA appear to be more broadly cardioprotective in the setting of obesity.122 Both SGLT2i and GLP1-RA may act on metabolic pathways and can be used for cardiovascular benefit across a range of metabolic and cardiovascular conditions. It is important to note that none of these medications were initially developed for their cardioprotective effects, and the precise mechanism by which they improve CVD outcomes remains an active area of investigation.
Albuminuria reduction is also associated with a slower rate of CKD progression and a lower likelihood of progression to ESKD. Residual albuminuria following anti-proteinuric treatment is a very strong risk factor for disease progression.123 The initial clinical trials of ACEi and ARBs made these therapies the cornerstone of CKD care for the next 20 years.124,125 Recent evidence demonstrates improved kidney outcomes following treatment with SGLT2i,126 GLP1-RA, 127 and non-steroidal MRAs on a background of ACEi/ARB.128 The data on steroidal MRAs and clinical kidney outcomes are less well established due to lack of randomized clinical trial data, though epidemiologic literature suggests some benefit.128,129
The benefits of newer antiproteinuric medications in slowing CKD progression are multifactorial and likely extend beyond albuminuria reduction alone, particularly as non-albuminuric patients also derive benefit.130 While other authors have pointed to post-hoc analyses of recent cardiovascular and kidney trials as exhibiting effect modification by baseline UACR, the p-values for interaction are non-significant in all but one trial (Table 4). Furthermore, these trials enrolled few patients with low levels of albuminuria and therefore subgroup analyses were underpowered.
Cardio-kidney protective medications have effects beyond their albuminuria reduction which may be important components of their effect on CKD outcomes. Both SGLT2i and GLP1-RA improve blood pressure control and induce weight loss, while MRAs provide aldosterone antagonism. With SGLT2i specifically, there is ongoing investigation into mechanisms related to tubuloglomerular feedback in reducing intraglomerular pressure, as well as anti-inflammatory131 and metabolic132 effects. GLP1-RA may offer renoprotection via reduced kidney inflammation and fibrosis,133 and results are awaited from the mechanistic REMODEL trial.134 Finally, new data has brought additional attention to the role of aldosterone antagonism in treating albuminuric CKD43,135 and preventing CVD events in these patients.136 Investigators are also pursuing a related approach, aldosterone synthase inhibition, to reduce CKD progression.137
Given the diversity of mechanism of action across cardio-kidney protective therapies with antiproteinuric effects, combination therapy using ACEi/ARB, SGLT2i, GLP1-RA, and MRA is an emerging area of research interest. While prior work of combination ACEi and ARB demonstrated reduced albuminuria without improving renal outcomes compared to monotherapy,138 this does not appear to be the case for combination treatment across the newer medication classes for diabetic kidney disease.117 In the FLOW trial, there was no evidence of effect modification for the composite kidney outcome based on background SGLT2i use,127 and in a meta-analysis of SGLT2i trials, there is no evidence of effect modification based on background GLP1-RA use.139 These findings provide preliminary evidence of independent effects of these two classes. Additional work has demonstrated additive benefit of ACEi/ARB and SGLT2i in non-diabetic kidney disease.140 Further work will be needed to assess any potential additive or synergistic benefits of ACEi/ARB, SGLT2i, GLP1-RA, and MRA and which patients should be considered for combination therapy.
As previously discussed, none of the more recent cardio-kidney protective drug classes were specifically designed for albuminuria reduction. Furthermore, current clinical trials do not assess whether improved outcomes are mediated by albuminuria reduction or whether albuminuria is instead a convenient biomarker of the yet undiscovered underlying mechanism. It is also important to recognize the heterogeneity in recent trials with respect to changes in albuminuria and clinical outcomes. This is especially true in the case of heart failure trials, where patients continue to exhibit kidney disease progression, or exhibit no renal benefit, despite improved CVD outcomes.141,142 This apparent therapeutic disconnect has been described for ARB, ARNI, SGLT2i, and non-steroidal MRA and is largely attributed to recruitment of patients with low background risk of CKD progression (e.g. those with lower albuminuria and less advanced CKD)141,143 or insufficient follow up time.141 Albuminuria data are also not routinely available in many previously cardiovascular trials.143 For example, the PARADIGM-HF trial (ARNI vs. ACEi) demonstrated worsening albuminuria in the ARNI group despite improvement in heart failure outcomes.144 This would seem to question the association between albuminuria reduction and improved CVD outcomes and suggest that the effects of ARNI are mediated by improved blood pressure and other cardiovascular intermediaries. However, the subsequent UK HARP III trial demonstrated no difference in kidney outcomes (and no worsening in albuminuria) among patients with CKD treated with ARNI versus ARB.145 Whether these differences are related to the study population – heart failure patients in PARADIGM-HF versus patients without heart failure in UK HARP III – is an important unanswered question. Other authors have hypothesized that physiologic differences in heart failure specifically underly the divergence in renal outcomes in trials of patients with heart failure versus CKD.141 A pooled analysis of Finerenone trials demonstrates cardiovascular and kidney benefit with non-steroidal MRA in a mixed heart failure and CKD population, suggesting that the limitations of present heart failure trial design may be responsible for reported lack of CKD benefit in these participants.146
Combination therapy is central to effective implementation of cardio-kidney protective therapies. Early, rapid sequence initiation and uptitration of these medications may prevent delays in care and limit therapeutic inertia.147 Patients on multi-drug therapy are most likely to achieve the greatest benefit, including longer event-free survival.117 Though not well studied with the SGLT2i or oral GLP1-RA, the hypertension literature demonstrates that multidrug combination pills decrease pill burden for patients and can improve medication adherence.148 Combination therapy may also reduce the need for ACEi/ARB and MRA discontinuation due to hyperkalemia. Given new data demonstrating that ACEi/ARB should not be pre-emptively stopped in advanced CKD due to worse cardiovascular outcomes,149,150 managing hyperkalemia with SGLT2i, loop diuretics, dietary modification, and potassium binders is essential to delivering high quality cardio-kidney care.151,152
The American Heart Association (AHA) report on Cardiovascular-Kidney-Metabolic (CKM) syndrome highlights the importance of albuminuria in CKD and heart failure. However, the authors defer recommending albuminuria screening until the later stages of CKM syndrome when impaired eGFR is already present.116 Given the evidence described in this review, it may be prudent for clinicians to consider screening for albuminuria using a broader definition of risk than the CKM framework.153 This could range from screening the general population (a strategy currently under evaluation by the United States Preventative Task Force Service for CKD surveillance)154 to a risk-based approach incorporating obesity, liver disease, insulin resistance, and behavioral features (low physical activity, smoking, etc.).
Albuminuria screening is guideline-recommended for high-risk populations such as those with diabetes, those with chronic kidney disease, those with hypertension, and those at high risk of clinical CVD or CKD (Table 5). Unfortunately, rates of albuminuria screening among currently indicated patient groups remain severely low.155–157 In the face of burgeoning treatments for CKD and preliminary cost-effectiveness analyses showing the benefits of screening,158 strategies to promote screening across a greater range of high-risk populations (e.g., hypertension, diabetes, CKD, atherosclerotic cardiovascular disease, heart failure, metabolic syndrome) are urgently needed.
Most patients eligible for albuminuria screening currently are managed in primary care offices, where competing demands, limited time, clinical complexity, and clinician lack of awareness to evolving guidelines may be barriers to screening.159 A 2014 study identified a major barrier to albuminuria screening for patients with non-diabetic CKD: the perception that it would not change management.160 Whether clinician attitudes have changed since introducing newer anti-proteinuric medications is unknown. Implementation and improvement scientists will be critical to increasing real-world screening rates by designing systematic, scalable, and adaptable interventions. Increased support for primary care clinicians and developing novel workflows may increase guideline-directed albuminuria screening and treatment implementation. Alternatively, some researchers have proposed that home-based, population-wide screening approaches may be more scalable, though potentially more costly to implement.161
Cardiovascular practices can improve the care of patients with CVD and those at risk for worsening CKM syndrome by incorporating routine albuminuria testing. Once identified, patients with albuminuria can be monitored more closely (Figure 3). The 2023 AHA Predicting Risk of Cardiovascular Events (PREVENT) cardiovascular risk calculator includes UACR for improved prediction of CVD events.162 Patients with elevated PREVENT scores are recommended for statin therapy, similar to the ASCVD risk calculator. In addition to providing valuable risk-stratification, UACR can also guide treatment intensification (Figure 3). There are ongoing efforts within Nephrology to implement rapid sequence uptitration of guideline-directed medical therapy for diabetic kidney disease, including ACEi/ARB, SGLT2i, GLP1-RA, and nsMRA, similar to the Cardiology approach to heart failure therapies.147 These same principles are directly applicable to cardiovascular clinical spaces for patients with CKM syndrome and CVD risk. Through appropriate UACR testing, cardiovascular practices will be at the forefront of detecting otherwise undiagnosed CKD through this approach. Patients can then be started on appropriate therapies based on their risk factor profile and/or referred to Nephrology, as appropriate.
Conclusion
In conclusion, albuminuria is a marker of widespread vascular dysfunction and subclinical cardiovascular risk that heralds evolving CKM dysfunction. As an inexpensive and non-invasive test, UACR provides a glimpse into the early development of CKM syndrome. Even low-grade albuminuria, below the traditional threshold of 30 mg/g, likely represents smoldering endothelial or vascular disease and carries substantial CVD and CKD risk. The literature on albuminuria as a CKM biomarker suggests that waiting for an eGFR decline to develop overlooks a key opportunity for disease prevention. Future research is needed to determine how broadly and how frequently to screen patients for albuminuria, whether it is cost-effective to treat low-grade albuminuria (for example, 10-30 mg/g), and how to equitably offer newer cardio-kidney protective therapies across the spectrum of CKM syndrome. Answering these questions may shift the clinical practice of cardiovascular risk reduction and improve population health.
AV
Dr. Ashish Verma
Nephrology · General NephrologyBoston Medical CenterashishvBoston, MA, USA